Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.30 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179525 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4PARP1 | |
| SCHEMBL18042843 | 0.80 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18042846 | 0.80 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5574863 | 0.79 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4PARP1 | |
| SCHEMBL18594506 | 0.79 | HDAC1 (0.37) | — | |
| SCHEMBL15711294 | 0.79 | HDAC1 (0.37) | — | |
| SCHEMBL17120406 | 0.77 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13108774 | 0.77 | EGFR (0.47) | — | |
| SCHEMBL13108772 | 0.77 | EGFR (0.47) | — | |
| SCHEMBL23620515 | 0.77 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | claimed |
| EP-2348096-A2 | Synthesis of hybrid block copolymers and uses thereof | Intezyne Technologies Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011088405-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2008006097-A2 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES LLC (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | CHRNB2 4628/4885CHRNB4 3446/4885CHRNA3 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.